Frontlight ResearchEarly access
CompletedPhase 3
Adjunctive Methylene Blue in Septic Shock
Key facts
- Who runs it
- Dr. Shannon M. Fernando
- Where
- Canada2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 50 people enrolled
- Started
- 2 Jun 2025
- Ended
- 6 Mar 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Methylene Blue
- Usual Care
- Record updated
- 19 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Adult patients (≥ 18 years of age) admitted to the ICU
- Diagnosed with septic shock (as per the Sepsis-3 Criteria): Suspected infection (i.e. initiation of antimicrobial therapy), coupled with initiation of vasopressor therapy to target a mean arterial pressure (MAP) > 65 mmHg (or as prescribed by the treating clinician), after adequate fluid resuscitation (as per treating clinician)
- Minimal norepinephrine dose of 0.1 mcg/kg/min for a minimum of 2 hours at the time of enrollment (i.e., the time of randomization)
Who cannot take part
- Pregnancy **Women of childbearing age (<50 years) should have a urine or beta hCG performed prior to enrolment
- Concurrent hemorrhagic, obstructive, or hypovolemic shock
- Known recent intake of selective serotonin re-uptake inhibitors (21 days for norfluoxetine, and 14 days for any other SSRI)
- Currently receiving linezolid
- Known Allergy to methylene blue, phenothiazines, or food dyes
- Known Personal or familial history of glucose-6-phophate dehydrogenase deficiency
- > 48 hours since initiation of norepinephrine
- > 48 hours since admission to ICU
- Anticipation of discontinuation of vasopressors in < 24 hours
- Plan for withdrawal of life support
- Major burn injury (>10% total body surface area)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Adjunctive Methylene BLUe in Septic SHock (BLUSH) is a single centre concealed-allocation parallel-group open-label randomized controlled pilot trial to ascertain the feasibility of a trial evaluating the efficacy and safety of adjunctive methylene blue infusion compared to usual care on outcomes of adult patients admitted to the intensive care unit with septic shock.
The 2 groups in the trial
- Methylene BlueTreatment being tested
Methylene Blue infusion: 0.5 mg/kg/hr for 6 hours daily (up to 3 days total).
- Usual CareExisting treatment, for comparison
Usual guideline-directed care for adult septic shock.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Adjunctive Methylene BLUe in Septic SHock: a Pilot Randomized Controlled Trial
- Record updated
- 19 March 2026